• Studies
• Mapping
• Meta-analysis
• Excluded 2

Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies		summary treatment patients method baseline characteristics risk of bias references						adverse eventsAE leading to drug discontinuationrelated AE (TRAE)related SAE (TRSAE)serious adverse eventsA EFFACER PCR-negative (end of follow-up)clinical deteriorationclinical improvementclinical improvement (14-day)clinical improvement (21-day)clinical improvement (28-day)clinical improvement (time to event analysis only)death D28deathsdeaths (time to event analysis only)emergency room observation for > 6 hours or hospitalizationhospitalizationhospitalization or deathICU admissionmechanical ventilationrecoveryRecovery (time to event analysis only)viral clearance viral clearance by day 14viral clearance by day 7 overview numeric bar chart forest plot medians figures uncontrolled O6
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
Hinks (ATOMIC2)   NCT04381962		RCT	azithromycin	standard of care	COVID 19 outpatients	some concern	147/148	inconclusive	inconclusive 9 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
PRINCIPLE   ISRCTN86534580		RCT	azithromycin	standard of care	COVID 19 outpatients	some concern	540/875	inconclusive	inconclusive 8 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias inconclusive 6 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
Thomas (zinc only)   NCT04342728		RCT	zinc	standard of care	COVID 19 outpatients	NA	58/50	inconclusive
Podder		RCT	ivermectin	standard of care	COVID 19 outpatients	high	32/30	inconclusive
Roozbeh   IRCT20200403046926N1		RCT	sofosbuvir and daclatasvir	standard of care	COVID 19 outpatients
bias due to missing outcome data	some concern
bias in measurement of the primary outcome	some concern
bias in selection of the reported result	some concern

" >some concern
30/30 inconclusive

Chahla
  NCT04784481 CRTivermectinstandard of careCOVID 19 outpatientshigh
110/144 suggested

• suggested 7.7-fold increase in clinical improvement (28-day) but with a low degree of certainty due to high risk of bias

Espitia-Hernandez NRaazithromycinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
28/7 uncontrolled

• [uncontrolled] negative PCR on day 10: 100.0% (28/28)

Espitia-Hernandez NRaivermectinstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
28/7 uncontrolled

• [uncontrolled] negative PCR on day 10: 100.0% (28/28)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).